Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression

Genomically amplified fibroblast growth factor receptor 1 (FGFR1) is an oncogenic driver in defined lung cancer subgroups and predicts sensibility against FGFR1 inhibitors in this patient cohort. The FGFR inhibitor nintedanib has recently been approved for treatment of lung adenocarcinoma and is cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Englinger, Bernhard, Lötsch, Daniela, Pirker, Christine, Mohr, Thomas, van Schoonhoven, Sushilla, Boidol, Bernd, Lardeau, Charles-Hugues, Spitzwieser, Melanie, Szabó, Pál, Heffeter, Petra, Lang, Irene, Cichna-Markl, Margit, Grasl-Kraupp, Bettina, Marian, Brigitte, Grusch, Michael, Kubicek, Stefan, Szakács, Gergely, Berger, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226575/
https://www.ncbi.nlm.nih.gov/pubmed/27367030
http://dx.doi.org/10.18632/oncotarget.10324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226575/
https://www.ncbi.nlm.nih.gov/pubmed/27367030
http://dx.doi.org/10.18632/oncotarget.10324

Ejemplares similares